Answers are grounded in this paper and cite their sources.
The E-MOTIVE trial demonstrates improved postpartum hemorrhage management in a large cohort, suggesting effective interventions for at-risk women.
( Lancet . 2025;405:1440-1441. doi: 10.1016/ S0140-6736(25)00573-2.) Reducing maternal deaths from postpartum hemorrhage (PPH) requires the early identification of at-risk women, swift and accurate detection of bleeding after childbirth, and immediate use of standardized treatment protocols. The E-MOTIVE trial, conducted across four countries (Kenya, South Africa, Nigeria, and Tanzania) in 80 hospitals and involving over 210,000 patients, aimed to improve the early detection and initial management of PPH. A key innovation was using a calibrated blood collection drape to more accurately measure blood loss. Once 300 mL of blood loss was detected, a bundled first-response treatment was triggered. This included uterine massage, administration of oxytocin and tranexamic acid, IV fluids, and genital tract examination. The trial significantly reduced severe PPH events (defined as >1000 mL of blood loss), need for rescue laparotomy, or death from 4.3% in the standard care group to 1.6% in the intervention group, highlighting the effectiveness of structured early response.
No takes yet. Share an insight, caveat, or question.
Ducloy-Bouthors et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: